Alzheimer’s Disease Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Alzheimer’s Disease Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Alzheimer’s Disease Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Alzheimer’s Disease, historical and forecasted epidemiology as well as the Alzheimer’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Alzheimer’s Disease Market by downloading the comprehensive report from DelveInsight @ Alzheimer’s Disease Treatment Market Size

 

Key Takeaways from the Alzheimer’s Disease Market Report

• In October 2024:- ACADIA Pharmaceuticals Inc.- A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Efficacy and Safety Studies of ACP-204 in Adults With Alzheimer’s Disease Psychosis. This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP.
• In October 2024:- AriBio Co., Ltd.- A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 Over 52 Weeks in Participants with Early Alzheimer’s Disease (Polaris-AD). The purpose of this Study is to evaluate the efficacy and safety of AR1001 in participants with Early Alzheimer’s Disease (AD).
• The projected growth in Alzheimer’s Disease market size is mainly driven by increasing diagnosed prevalence, increasing awareness, and improved diagnosis along with anticipated approval of emerging therapies in the 7MM.
• As per DelveInsight analysis, in 2023, there were approximately 15.4 million total diagnosed prevalent cases of Alzheimer’s disease in the 7MM. These cases are projected to increase further during the forecast period, due to increasing geriatric population globally.
• According to DelveInsight’s analysis of Alzheimer’s disease by severity, in 2023, there were approximately 8.4, 3.2, 2.3, and 1.5 million cases of MCI, mild, moderate, and severe dementia, respectively, across the 7MM, which are expected to increase by 2034.
• As per estimates based on DelveInsight’s epidemiology model for Alzheimer’s disease, the gender distribution of the disease suggests a female predominance across the 7MM, with approximately 5.1 million male and 10 million female cases in the 7MM, in 2023.
• The leading Alzheimer’s Disease Companies such as Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., and others.
• Promising Alzheimer’s Disease Therapies such as Wujia Yizhi granules, Semaglutide, Gantenerumab, E2814, Lecanemab, and others.

 

Gain a competitive edge in the Alzheimer’s Disease Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Alzheimer’s Disease Treatment Drugs

 

Alzheimer’s Disease Epidemiology Segmentation in the 7MM

• Alzheimer’s Disease Age-specific Cases
• Total Alzheimer’s Disease Diagnosed Prevalent Cases
• Alzheimer’s Disease Gender-specific Cases
• Alzheimer’s Disease Severity-specific Cases

 

Alzheimer’s Disease Market Insights

There is currently no cure for Alzheimer’s disease, even though early initiation and treatment persistence is considered important in relieving the clinical symptoms of Alzheimer’s disease. Earlier diagnosis is important for enabling symptomatic therapies, treating behavioral symptoms, and adopting lifestyle changes commonly used to reduce the risk of developing dementia and eventually slow disease progression. 

 

Discover key developments and opportunities in the Alzheimer’s Disease Market. Click here to learn more from DelveInsight’s latest report @ Alzheimer’s Disease Market Size

 

Marketed Alzheimer’s disease Drugs

• ADUHELM (aducanumab): Biogen and Eisai
• LEQEMBI (lecanemab): Biogen and Eisai
• Donanemab (LY3002813): Eli Lilly

 

Emerging Alzheimer’s disease Drugs

• NE3107: BioVie
• Simufilam (PTI-125): Cassava Sciences
• Hydromethylthionine mesylate/TRx0237: TauRx Therapeutics
• ALZ-801 (valiltramiprosate): Alzheon
• Fosgonimeton (ATH-1017): Athira Pharma
• Buntanetap: Annovis Bio
• ANAVEX2-73 (blarcamesine): Anavex Life Sciences

 

Alzheimer’s Disease Market Outlook

The drugs currently available to treat many of the symptoms associated with dementia are working by increasing activity levels of some brain neurotransmitters, such as acetylcholine, serotonin, and noradrenaline, or by reducing the activity of other neurotransmitters, such as glutamate and dopamine. Due to associated side effects, it is also important to personalize dementia symptomatic therapeutics considering patients’ comorbidities and their respective therapies. Effects on cardiac function, drug elimination, and other interactions should be assessed case by case.

 

Download DelveInsight’s Alzheimer’s Disease Market report today and stay ahead in this rapidly evolving field. @ Alzheimer’s Disease Clinical Trials

 

Scope of the Alzheimer’s Disease Market Report

• Coverage- 7MM
• Alzheimer’s Disease Companies- Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., and others.
• Alzheimer’s Disease Therapies- Wujia Yizhi granules, Semaglutide, Gantenerumab, E2814, Lecanemab, and others.
• Alzheimer’s Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Alzheimer’s Disease Unmet Needs, KOL’s views, Analyst’s views, Alzheimer’s Disease Market Access and Reimbursement

 

Download the report to understand which factors are driving Alzheimer’s Disease Market Trends @ Alzheimer’s Disease Market Trends

 

Table of Content

1. Key Insights

2. Report Introduction

3. Alzheimer’s Disease Market Overview at a Glance

4. Methodology of Alzheimer’s Disease Epidemiology and Market

5. Executive Summary of Alzheimer’s Disease

6. Key events

7. Disease Background and Overview

8. Alzheimer’s Disease Patient Journey of Alzheimer’s Disease

9. Alzheimer’s Disease Epidemiology and Patient Population

10. Alzheimer’s Disease Marketed Drugs

11. Emerging Alzheimer’s Disease Therapies

12. Alzheimer’s Disease Market: The Seven Major Market Analysis

13. Alzheimer’s Disease KOL views

14. SWOT Analysis

15. Alzheimer’s Disease Unmet Needs

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/